Fatty acid oxidation inhibitors in the treatment of stable angina

Abstract

Ranolazine is a newer drug working as a partial fatty acid oxidase inhibitor, that will inhibit the late sodium currents of the cardiac myocytes and reduces the sodium and overall, calcium overload that occurs in ischemia. In turn, this results in ventricular and myocardial relaxation, aiding in perfusion and recovery. In establishing itself as a metabolic modulator, the hemodynamics of the myocardial are not altered to an extent that other therapeutic treatments pose. The following clinical trials support the positive efficacy in the use of Ranolazine as monotherapy or as adjuvant therapy in CSA. Continuous study will be useful in in investigating potential future applications in the treatment of CSA.